Dantrolene : From Malignant Hyperthermia to Alzheimer’s Disease

(E-pub Ahead of Print)

Author(s): Yun Shi, Yong Wang, Huafeng Wei*.

Journal Name: CNS & Neurological Disorders - Drug Targets

Become EABM
Become Reviewer


Background & Objective: Dantrolene, a ryanodine receptor antagonist, is primarily known as the only clinically acceptable and effective treatment for malignant hyperthermia (MH). Inhibition of ryanodine receptor (RyR) by dantrolene decreases the abnormal calcium release from the sarcoplasmic reticulum (SR) or endoplasmic reticulum (ER), where RyR is located on. Recently, emerging researches on dissociated cells, brains slices, live animal models and patients demonstrate that altered RyR expression and function can also play a vital role in the pathogenesis of Alzheimer’s disease (AD). Therefore, dantrolene is now widely studied as a novel treatment for AD, targeting the blockade of RyR channels or other alternative pathways, such as the inhibitory effects of NMDA glutamate receptors and the effects of ER-mitochondria connection. However, the therapeutic effects are not consistent. Conclusion: In this review, we focus on the relationship between the altered RyR expression and function and the pathogenesis of AD, and the potential application of dantrolene as a novel treatment for the disease.

Keywords: Alzheimer’s disease, dantrolene, therapy, ryanodine receptor, calcium, amyloid

Rights & PermissionsPrintExport Cite as

Article Details

(E-pub Ahead of Print)
DOI: 10.2174/1871527317666180619162649
Price: $95

Article Metrics

PDF: 12